Literature DB >> 15162896

Treatment of pain syndromes with venlafaxine.

Dale R Grothe1, Brian Scheckner, Dominick Albano.   

Abstract

Major depressive disorder (MDD) and anxiety disorders such as generalized anxiety disorder (GAD) are often accompanied by chronic painful symptoms. Examples of such symptoms are backache, headache, gastrointestinal pain, and joint pain. In addition, pain generally not associated with major depression or an anxiety disorder, such as peripheral neuropathic pain (e.g., diabetic neuropathy and postherpetic neuralgia), cancer pain, and fibromyalgia, can be challenging for primary care providers to treat. Antidepressants that block reuptake of both serotonin and norepinephrine, such as the tricyclic antidepressants (e.g., amitriptyline), have been used to treat pain syndromes in patients with or without comorbid MDD or GAD. Venlafaxine, a serotonin and norepinephrine reuptake inhibitor, has been safe and effective in animal models, healthy human volunteers, and patients for treatment of various pain syndromes. The use of venlafaxine for treatment of pain associated with MDD or GAD, neuropathic pain, headache, fibromyalgia, and postmastectomy pain syndrome is reviewed. Currently, no antidepressants, including venlafaxine, are approved for the treatment of chronic pain syndromes. Additional randomized, controlled trials are necessary to fully elucidate the role of venlafaxine in the treatment of chronic pain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15162896     DOI: 10.1592/phco.24.6.621.34748

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  11 in total

1.  Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.

Authors:  Kathleen C Light; Edith E Bragdon; Karen M Grewen; Kimberly A Brownley; Susan S Girdler; William Maixner
Journal:  J Pain       Date:  2009-05       Impact factor: 5.820

Review 2.  The narcotic bowel syndrome: a recent update.

Authors:  Douglas Drossman; Eva Szigethy
Journal:  Am J Gastroenterol Suppl       Date:  2014-09-10

Review 3.  [Depression in cancer patients].

Authors:  Barbara Sperner-Unterweger
Journal:  Wien Med Wochenschr       Date:  2015-07-04

4.  Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial.

Authors:  Changsu Han; Chi-Un Pae; Bun-Hee Lee; Young-Hoon Ko; Prakash S Masand; Ashwin A Patkar; Sook-Haeng Joe; In-Kwa Jung
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

5.  Pharmacologic management of chronic pain.

Authors:  Hue Jung Park; Dong Eon Moon
Journal:  Korean J Pain       Date:  2010-05-31

6.  Pain associated with specific anxiety and depressive disorders in a nationally representative population sample.

Authors:  Katja Beesdo; Frank Jacobi; Jürgen Hoyer; Nancy C P Low; Michael Höfler; Hans-Ulrich Wittchen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-04-10       Impact factor: 4.328

Review 7.  Medications for alcohol use disorders: An overview.

Authors:  Mohammed Akbar; Mark Egli; Young-Eun Cho; Byoung-Joon Song; Antonio Noronha
Journal:  Pharmacol Ther       Date:  2017-12-02       Impact factor: 12.310

8.  Alleviating neuropathy of diabetic foot ulcer by co-delivery of venlafaxine and matrix metalloproteinase drug-loaded cellulose nanofiber sheets: production, in vitro characterization and clinical trial.

Authors:  Rokhsareh Meamar; Sana Chegini; Jaleh Varshosaz; Ashraf Aminorroaya; Masoud Amini; Mansour Siavosh
Journal:  Pharmacol Rep       Date:  2021-04-07       Impact factor: 3.024

9.  Serum 3-Hydroxybutyrate in Patients with Psychogenic Somatoform Symptoms May Be a Predictor of the Effectiveness of Sertraline and Venlafaxine.

Authors:  Norihiro Saito; Masamichi Itoga; Satoko Minakawa; Hiroyuki Kayaba
Journal:  Int J Gen Med       Date:  2021-05-10

10.  Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study.

Authors:  Tulay Kus; Gokmen Aktas; Gokay Alpak; Mehmet Emin Kalender; Alper Sevinc; Seval Kul; Mithat Temizer; Celaletdin Camci
Journal:  Support Care Cancer       Date:  2015-11-07       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.